Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
The pharmaceutical sector is entering new and unfamiliar territory. Key assumptions, such as the unrivalled profitability of the US market and the reliance on large M&A to spur growth, are getting a serious shake-up. From the FDA's shifting temperament and the ripple effects of the IRA, commercial disruptions, dealmaking ambiguities and…
Despite the initial shock of the COVID-19 pandemic, 2020 was a standout year for biopharma. The top 600 biopharma companies added $487bn in market capitalisation, and…
Biopharma’s role in trying to bring the COVID-19 pandemic to an end has made household names of companies large and small, and cutting-edge technologies like mRNA…
Biopharma was not exempt from the initial shock of a global pandemic, but the worst projections have not happened and the initial beneficiaries have now emerged. After a…
This year's edition of the Evaluate Pharma World Preview arrives at a time when the global economy is reeling. The impact of COVID-19 has so far wiped $7.85bn off…
Biopharma and Medtech are leading the fight against COVID-19, but are not immune from the significant economic impact of the pandemic. The COVID-19 pandemic is having a…
What will the orphan drug landscape look like in 2024? Big pharma's recent dominance of the orphan market has fuelled calls to reform the orphan drug act in the US.…
2019 was a standout year for biopharma, anchored by strong fourth quarter markets and dealmaking. Following a difficult end to 2018, the biopharma industry recovered…
The Evaluate Vantage 2020 Preview predicts a rocky year ahead, with areas of significant growth contrasting with investor uncertainty. The industry closed 2019 with a…
Mega-deals mask a significant decline in M&A activity for pharma and medtech The Evaluate Vantage Half-Year Review 2019 summaries the most significant trends across…
Worldwide prescription drugs sales predicted to reach $1.18trn in 2024, with a compound annual growth of 6.9%, significantly higher than the 1.7% CAGR between…